GrowthDifferentiation Factor 8 Pipeline Review, H2 2019
Summary
According to the recently published report 'GrowthDifferentiation Factor 8 Pipeline Review, H2 2019'; Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN pipeline Target constitutes close to 10 molecules.
Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN Myostatin also known as growth differentiation factor 8 or GDF8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta TGF superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.
The report 'GrowthDifferentiation Factor 8 Pipeline Review, H2 2019' outlays comprehensive information on the Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in PreRegistration, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 3 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Musculoskeletal Disorders, Hematological Disorders and Oncology which include indications Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy SMA, Duchenne Muscular Dystrophy, Anemia, CharcotMarieTooth Disease, Fibrodysplasia Ossificans Progressiva Myositis Ossificans Progressiva, LimbGirdle Muscular Dystrophy, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis, Neuro Muscular Disorders, PostEssential Thrombocythemia Myelofibrosis PostET MF, PostPolycythemia Vera Myelofibrosis PPVMF and Thalassemia.
Scope
The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN
The report reviews Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN targeted therapeutics and enlists all their major and minor projects
The report assesses Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 Myostatin or GDF8 or MSTN development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope